We are analyzing https://link.springer.com/article/10.1186/s40425-016-0152-y.

Title:
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy | Journal for ImmunoTherapy of Cancer
Description:
Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, an increase in overall survival has been demonstrated with anti-CTLA-4 and PD-1 inhibition. However, a plethora of immune-mediated adverse events has been reported with these agents. Immune-mediated cardiotoxicity induced by checkpoint inhibitors has been reported in single cases with variable presentation, including myocarditis and pericarditis. Among six clinical cancer centers with substantial experience in the administration of immune-checkpoint blocking antibodies, eight cases of immune-related cardiotoxicity after ipilimumab and/or nivolumab/pembrolizumab were identified. Diagnostic findings, treatment and follow-up are reported. A large variety of cardiotoxic events with manifestations such as heart failure, cardiomyopathy, heart block, myocardial fibrosis and myocarditis was documented. This is the largest case series to date describing cardiotoxicity of immune-checkpoint blocking antibodies. Awareness, monitoring of patients with pre-existing cardiac disorders and prompt evaluation by the treatment team is essential. Treatment including application of steroids is critical for patient safety.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

pubmed, article, melanoma, ipilimumab, cardiac, patient, google, scholar, cancer, myocarditis, patients, treatment, case, metastatic, cas, treated, including, clinical, heart, failure, antibodies, immunerelated, disease, left, central, therapy, institutional, antipd, tumor, review, effects, ventricular, ctla, events, cardiomyopathy, checkpoint, myocardial, pembrolizumab, immunotherapy, adverse, fibrosis, board, side, center, university, revealed, developed, cardiotoxicity, blocking, hodi,

Topics {✒️}

dana-farber cancer institute friedrich-alexander-university erlangen-nürnberg immune-checkpoint blocking antibodies immune-related adverse events anti-programmed-death-receptor-1 treatment immune-related adverse event immune-mediated adverse events rectus muscle wild-type immune-related cardiac syndromes pd1 blocking immunotherapy immune-checkpoint antibody treatment immune-related toxicity induced immune-related toxicity experienced autologous anti-mage-a3 article download pdf past medical history immune-mediated etiology triggered azadeh tajmir-riahi anti-pd1 antibody pembrolizumab immune-mediated cardiotoxicity induced ctla-4 blocking antibody pre-existing cardiac disorders randomised dose-comparison cohort ipilimumab-refractory advanced melanoma ventricular tachycardia/ventricular fibrillation pre-existent cardiac pathology bacterial/fungal cultures ruled suggest stress-induced ischemia cancer lucie heinzerling prior cardiac history pd-1 receptor-deficient mice institutional review board immune-related toxicity anti-ctla-4 antibodies [15–20] anti-ctla-4 antibodies immunotherapy cancer 4 immune-related cardiotoxicity checkpoint inhibitor therapy cardiologic side effects immune checkpoint blockade immune-induced myocarditis immune-related colitis fixed perfusion defect institutional review boards immunostimulatory monoclonal antibody phase ii decog-study microscopic findings including anti-pd1 antibodies anti-pd1 antibodies [10 renal cell cancer

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
         description:Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, an increase in overall survival has been demonstrated with anti-CTLA-4 and PD-1 inhibition. However, a plethora of immune-mediated adverse events has been reported with these agents. Immune-mediated cardiotoxicity induced by checkpoint inhibitors has been reported in single cases with variable presentation, including myocarditis and pericarditis. Among six clinical cancer centers with substantial experience in the administration of immune-checkpoint blocking antibodies, eight cases of immune-related cardiotoxicity after ipilimumab and/or nivolumab/pembrolizumab were identified. Diagnostic findings, treatment and follow-up are reported. A large variety of cardiotoxic events with manifestations such as heart failure, cardiomyopathy, heart block, myocardial fibrosis and myocarditis was documented. This is the largest case series to date describing cardiotoxicity of immune-checkpoint blocking antibodies. Awareness, monitoring of patients with pre-existing cardiac disorders and prompt evaluation by the treatment team is essential. Treatment including application of steroids is critical for patient safety.
         datePublished:2016-08-16T00:00:00Z
         dateModified:2016-08-16T00:00:00Z
         pageStart:1
         pageEnd:11
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s40425-016-0152-y
         keywords:
            Checkpoint inhibitor
            Immune-related adverse events
            Melanoma
            Immunotherapy
            Myocarditis
            Cardiomyopathy
            Ipilimumab
            Nivolumab
            Pembrolizumab
            Oncology
            Immunology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-016-0152-y/MediaObjects/40425_2016_152_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-016-0152-y/MediaObjects/40425_2016_152_Fig2_HTML.gif
         isPartOf:
            name:Journal for ImmunoTherapy of Cancer
            issn:
               2051-1426
            volumeNumber:4
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Lucie Heinzerling
               affiliation:
                     name:University Hospital Erlangen
                     address:
                        name:University Hospital Erlangen, Erlangen, Germany
                        type:PostalAddress
                     type:Organization
                     name:University Hospital Erlangen
                     address:
                        name:Department of Dermatology, University Hospital Erlangen, Erlangen, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Patrick A. Ott
               affiliation:
                     name:Dana Farber Cancer Institute
                     address:
                        name:Dana Farber Cancer Institute, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:F. Stephen Hodi
               affiliation:
                     name:Dana Farber Cancer Institute
                     address:
                        name:Dana Farber Cancer Institute, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Aliya N. Husain
               affiliation:
                     name:University of Chicago Comprehensive Cancer Center and Pathology
                     address:
                        name:University of Chicago Comprehensive Cancer Center and Pathology, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Azadeh Tajmir-Riahi
               affiliation:
                     name:University Hospital Erlangen
                     address:
                        name:University Hospital Erlangen, Erlangen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hussein Tawbi
               affiliation:
                     name:University of Texas MD Anderson Center
                     address:
                        name:University of Texas MD Anderson Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Matthias Pauschinger
               affiliation:
                     name:Paracelsus University Hospital Nuremberg
                     address:
                        name:Paracelsus University Hospital Nuremberg, Nürnberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Thomas F. Gajewski
               affiliation:
                     name:University of Chicago Comprehensive Cancer Center and Pathology
                     address:
                        name:University of Chicago Comprehensive Cancer Center and Pathology, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Evan J. Lipson
               affiliation:
                     name:Sidney Kimmel Comprehensive Cancer Center
                     address:
                        name:Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jason J. Luke
               affiliation:
                     name:University of Chicago Comprehensive Cancer Center and Pathology
                     address:
                        name:University of Chicago Comprehensive Cancer Center and Pathology, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
      description:Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, an increase in overall survival has been demonstrated with anti-CTLA-4 and PD-1 inhibition. However, a plethora of immune-mediated adverse events has been reported with these agents. Immune-mediated cardiotoxicity induced by checkpoint inhibitors has been reported in single cases with variable presentation, including myocarditis and pericarditis. Among six clinical cancer centers with substantial experience in the administration of immune-checkpoint blocking antibodies, eight cases of immune-related cardiotoxicity after ipilimumab and/or nivolumab/pembrolizumab were identified. Diagnostic findings, treatment and follow-up are reported. A large variety of cardiotoxic events with manifestations such as heart failure, cardiomyopathy, heart block, myocardial fibrosis and myocarditis was documented. This is the largest case series to date describing cardiotoxicity of immune-checkpoint blocking antibodies. Awareness, monitoring of patients with pre-existing cardiac disorders and prompt evaluation by the treatment team is essential. Treatment including application of steroids is critical for patient safety.
      datePublished:2016-08-16T00:00:00Z
      dateModified:2016-08-16T00:00:00Z
      pageStart:1
      pageEnd:11
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s40425-016-0152-y
      keywords:
         Checkpoint inhibitor
         Immune-related adverse events
         Melanoma
         Immunotherapy
         Myocarditis
         Cardiomyopathy
         Ipilimumab
         Nivolumab
         Pembrolizumab
         Oncology
         Immunology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-016-0152-y/MediaObjects/40425_2016_152_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-016-0152-y/MediaObjects/40425_2016_152_Fig2_HTML.gif
      isPartOf:
         name:Journal for ImmunoTherapy of Cancer
         issn:
            2051-1426
         volumeNumber:4
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Lucie Heinzerling
            affiliation:
                  name:University Hospital Erlangen
                  address:
                     name:University Hospital Erlangen, Erlangen, Germany
                     type:PostalAddress
                  type:Organization
                  name:University Hospital Erlangen
                  address:
                     name:Department of Dermatology, University Hospital Erlangen, Erlangen, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Patrick A. Ott
            affiliation:
                  name:Dana Farber Cancer Institute
                  address:
                     name:Dana Farber Cancer Institute, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:F. Stephen Hodi
            affiliation:
                  name:Dana Farber Cancer Institute
                  address:
                     name:Dana Farber Cancer Institute, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Aliya N. Husain
            affiliation:
                  name:University of Chicago Comprehensive Cancer Center and Pathology
                  address:
                     name:University of Chicago Comprehensive Cancer Center and Pathology, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Azadeh Tajmir-Riahi
            affiliation:
                  name:University Hospital Erlangen
                  address:
                     name:University Hospital Erlangen, Erlangen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hussein Tawbi
            affiliation:
                  name:University of Texas MD Anderson Center
                  address:
                     name:University of Texas MD Anderson Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Matthias Pauschinger
            affiliation:
                  name:Paracelsus University Hospital Nuremberg
                  address:
                     name:Paracelsus University Hospital Nuremberg, Nürnberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Thomas F. Gajewski
            affiliation:
                  name:University of Chicago Comprehensive Cancer Center and Pathology
                  address:
                     name:University of Chicago Comprehensive Cancer Center and Pathology, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Evan J. Lipson
            affiliation:
                  name:Sidney Kimmel Comprehensive Cancer Center
                  address:
                     name:Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jason J. Luke
            affiliation:
                  name:University of Chicago Comprehensive Cancer Center and Pathology
                  address:
                     name:University of Chicago Comprehensive Cancer Center and Pathology, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal for ImmunoTherapy of Cancer
      issn:
         2051-1426
      volumeNumber:4
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University Hospital Erlangen
      address:
         name:University Hospital Erlangen, Erlangen, Germany
         type:PostalAddress
      name:University Hospital Erlangen
      address:
         name:Department of Dermatology, University Hospital Erlangen, Erlangen, Germany
         type:PostalAddress
      name:Dana Farber Cancer Institute
      address:
         name:Dana Farber Cancer Institute, Boston, USA
         type:PostalAddress
      name:Dana Farber Cancer Institute
      address:
         name:Dana Farber Cancer Institute, Boston, USA
         type:PostalAddress
      name:University of Chicago Comprehensive Cancer Center and Pathology
      address:
         name:University of Chicago Comprehensive Cancer Center and Pathology, Chicago, USA
         type:PostalAddress
      name:University Hospital Erlangen
      address:
         name:University Hospital Erlangen, Erlangen, Germany
         type:PostalAddress
      name:University of Texas MD Anderson Center
      address:
         name:University of Texas MD Anderson Center, Houston, USA
         type:PostalAddress
      name:Paracelsus University Hospital Nuremberg
      address:
         name:Paracelsus University Hospital Nuremberg, Nürnberg, Germany
         type:PostalAddress
      name:University of Chicago Comprehensive Cancer Center and Pathology
      address:
         name:University of Chicago Comprehensive Cancer Center and Pathology, Chicago, USA
         type:PostalAddress
      name:Sidney Kimmel Comprehensive Cancer Center
      address:
         name:Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
         type:PostalAddress
      name:University of Chicago Comprehensive Cancer Center and Pathology
      address:
         name:University of Chicago Comprehensive Cancer Center and Pathology, Chicago, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Lucie Heinzerling
      affiliation:
            name:University Hospital Erlangen
            address:
               name:University Hospital Erlangen, Erlangen, Germany
               type:PostalAddress
            type:Organization
            name:University Hospital Erlangen
            address:
               name:Department of Dermatology, University Hospital Erlangen, Erlangen, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Patrick A. Ott
      affiliation:
            name:Dana Farber Cancer Institute
            address:
               name:Dana Farber Cancer Institute, Boston, USA
               type:PostalAddress
            type:Organization
      name:F. Stephen Hodi
      affiliation:
            name:Dana Farber Cancer Institute
            address:
               name:Dana Farber Cancer Institute, Boston, USA
               type:PostalAddress
            type:Organization
      name:Aliya N. Husain
      affiliation:
            name:University of Chicago Comprehensive Cancer Center and Pathology
            address:
               name:University of Chicago Comprehensive Cancer Center and Pathology, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Azadeh Tajmir-Riahi
      affiliation:
            name:University Hospital Erlangen
            address:
               name:University Hospital Erlangen, Erlangen, Germany
               type:PostalAddress
            type:Organization
      name:Hussein Tawbi
      affiliation:
            name:University of Texas MD Anderson Center
            address:
               name:University of Texas MD Anderson Center, Houston, USA
               type:PostalAddress
            type:Organization
      name:Matthias Pauschinger
      affiliation:
            name:Paracelsus University Hospital Nuremberg
            address:
               name:Paracelsus University Hospital Nuremberg, Nürnberg, Germany
               type:PostalAddress
            type:Organization
      name:Thomas F. Gajewski
      affiliation:
            name:University of Chicago Comprehensive Cancer Center and Pathology
            address:
               name:University of Chicago Comprehensive Cancer Center and Pathology, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Evan J. Lipson
      affiliation:
            name:Sidney Kimmel Comprehensive Cancer Center
            address:
               name:Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
               type:PostalAddress
            type:Organization
      name:Jason J. Luke
      affiliation:
            name:University of Chicago Comprehensive Cancer Center and Pathology
            address:
               name:University of Chicago Comprehensive Cancer Center and Pathology, Chicago, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:University Hospital Erlangen, Erlangen, Germany
      name:Department of Dermatology, University Hospital Erlangen, Erlangen, Germany
      name:Dana Farber Cancer Institute, Boston, USA
      name:Dana Farber Cancer Institute, Boston, USA
      name:University of Chicago Comprehensive Cancer Center and Pathology, Chicago, USA
      name:University Hospital Erlangen, Erlangen, Germany
      name:University of Texas MD Anderson Center, Houston, USA
      name:Paracelsus University Hospital Nuremberg, Nürnberg, Germany
      name:University of Chicago Comprehensive Cancer Center and Pathology, Chicago, USA
      name:Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
      name:University of Chicago Comprehensive Cancer Center and Pathology, Chicago, USA

External Links {🔗}(157)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.42s.

LINK . SPRINGER . COM {}